Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.

Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.

Dizal got a lucky break with golidocitinib, and now mid-stage data back the project’s activity in T-cell lymphoma.

Daiichi aims to expand valemetostat into a new use, but Haihe Biopharma isn't far behind.